Skip to product information
1 of 1

GeneBio Systems

Recombinant Human HDAC8/HDACL1 Protein (GST Tag)

Recombinant Human HDAC8/HDACL1 Protein (GST Tag)

SKU:PKSH031385

Regular price $1,224.00 CAD
Regular price Sale price $1,224.00 CAD
Sale Sold out
Shipping calculated at checkout.

Size: 100μg

Storage: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.

Shipping: This product is provided as lyophilized powder which is shipped with ice packs.

Exp date: 12 months

Category ID_II: Recombinant Proteins

Category ID_III: Others

Abbreviation:

Target Synonym: CDA07;CDLS5;HD8;HDACL1;MRXS6;RPD3;WTS

Research Areas: Cardiovascular;epigenetics and nuclear signal;Stem cells

Conjugation:

Target Species: Human

Expression Host: Baculovirus-Insect Cells

Application:

Fusion tag: C-GST

UNIProt ID: Q9BY41

Accession: NP_060956.1

Background: Histone deacetylase 8, also known as HDAC8 and HDACL1, is a nucleus and cytoplasm protein which belongs to thehistone deacetylase family and HD type 1 subfamily. Histone deacetylases (HDACs) are a growing family of enzymes implicated in transcriptional regulation by affecting the acetylation state of core histones in the nucleus of cells.HDAC8 / HDACL1 is weakly expressed in most tissues. It expressed at higher level in heart, brain, kidney and pancreas and also in liver, lung, placenta, prostate and kidney. HDAC8 / HDACL1 is responsible for the deacetylation of lysine residues on the N-terminal part of the core histones ( H2A, H2B, H3 and H4 ). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. HDAC8 / HDACL1 may play a role in smooth muscle cell contractility. HDAC8 / HDACL1 may be a potential drug target for neuroblastoma differentiation therapy using selective inhibitors, avoiding unspecific side effects.

Concentration:

Activity: Not validated for activity

Sequence: Met 1-Val 377

Purity: > 88 % as determined by reducing SDS-PAGE.

Formulation: Lyophilized from sterile 50mM Tris, 100mM NaCl, 0.5mM PMSF, 10% glycerol, pH 8.0
Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.

Reconstitution: Please refer to the printed manual for detailed information.

Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method.

Calculated MW: 68.0 kDa

ObservedMW: 68 kDa

View full details